Combination of flavopiridol and embelin effectively inhibit cell growth in hepatocellular carcinoma depending on regulatory relationship between CDK6 and XIAP

Medicinal Chemistry Research

Volumn 21, Issue 11, 2012, Pages 3369-3375

  Che, Yufang ^a   Zhang, David Y ^b   Ye, Fei ^b   Wu, Benyan ^a   Jiang, Bo ^c  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

CDK6; Embelin; Flavopiridol; Hepatocellular carcinoma; XIAP

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; EMBELIN; FLAVOPIRIDOL; SMALL INTERFERING RNA; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE G1 PHASE; CELL STRAIN HEPG2; CELL VIABILITY; DOWN REGULATION; EXPRESSION VECTOR; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION;

EID: 84871428427     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9867-y     Document Type: Article

References (33)

1. Alonso M, Tamasdan C, Miller DC et al (2003) Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol Cancer Ther 2:139-150
2. Amir TF, Grant S, Karp JE (2010) Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev 36:142-150
3. Befeler AS, Di Bisceglie AM (2002) Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122:1609-1619
4. Bosch FX, Ribes et al (1999) Epidemiology of primary liver cancer. Semin Liver Dis 19:271-285
5. Bosch FX, Ribes J, Diaz M et al (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127:S5-S16
6. Demidenko ZN, Blagosklonny MV (2004) Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res 64:3653-3660
7. Deveraux QL, Reed JC (1999) IAP family proteins-suppressors of apoptosis. Genes Dev 13:239-252
8. Gomez LA, de Las Pozas A, Perez-Stable C (2006) Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells. Mol Cancer Ther 5(5):1216-1226
9. Grazi GL, Ercolani et al (2001) Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 234:71-78
10. Hagymási K, Tulassay Z (2010) New possibilities of targeted therapy in the treatment of hepatocellular carcinoma in view of molecular biology. Orv Hetil 151(43):1763-1768
11. Holcik M, Gibson H, Korneluk RG (2001) XIAP: Apoptotic brake and promising therapeutic target. Apoptosis 6:253-261
12. Jemal A, Ward E, Hao Y et al (2005) Trends in the leading causes of death in the United States, 1970-2002. JAMA 294:1255-1259
13. Jiang J, Matranga CB, Cai D et al (2003) Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. Cancer Res 63:7410-7422
14. Kim DM, Koo SY, Jeon K et al (2003) Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-Alpha or TNFrelated apoptosis-inducing ligand in human cancer cell lines. Cancer Res 63:621-626
15. Klasa RJ, List AF, Cheson BD (2001) Rational approaches to design of therapeutics targeting molecular markers. Hematology Am Soc Hematol Educ Program: 443-62
16. Lin TY, Lee et al (1987) Role of surgery in the treatment of primary carcinoma of the liver: A 31-year experience. Br J Surg 74:839-842
17. Litz J, Carlson P, Warshamana-Greene GS et al (2003) Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction. Clin Cancer Res 9:4586-4594
18. Melanie BT, Jaffe D, Choti MM et al (2010) Hepatocellular carcinoma: consensus recommendations of the national cancer institute clinical trials planning meeting. J Clin Oncol 28:3994-4005
19. Okuda K, Obata et al (1984) Prognosis of primary hepatocellular carcinoma. Hepatology 4:3S-6S
20. Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153-156
21. Rizzolio F, Tuccinardi T, Caligiuri L et al (2010) CDK inhibitors: from the bench to clinical trials. Curr Drug Targe 11(3):279-290
22. Salvesen GS, Duckett CS (2002) IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3:401-410
23. Sato S, Kajiyama Y, Sugano M et al (2004) Flavopiridol as a radiosensitizer for esophageal cancer cell lines. Dis Esophagus 17: 338-344
24. Schwartz GK (2005) Development of cell cycle active drugs for the treatment of gastrointestinal cancers: A new approach to cancer therapy. J Clin Oncol 23:4499-4508
25. Shah MA, Kortmansky J, Motwani M et al (2005) A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 11(10):3836-3845
26. Simonetti RG, Liberati A, Angiolini C et al (1997) Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials. Ann Oncol 8:117-136
27. Thomas SL (2010) New agents in chronic lymphocytic leukemia. Curr Hematol Malig Rep 5:29-34
28. Whittaker S, Marais R, Zhu AX (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29(36):4989-5005
29. Wittmann S, Bali P, Donapaty S et al (2003) Flavopiridol downregulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res 63:93-99
30. Wu K, D'Amico M, Wang C et al (2005) A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines. Invest New Drugs 23:299-309
31. Ying-Hong Shi, Ding W-X, Zhou Jian et al (2008) Expression of X-Linked Inhibitor-of-Apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology 48(2):497-507
32. Zhai S, Sendero wicz AM, Sausville EA et al (2002) Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother 36:905-911
33. Zhu AX (2006) Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be Oncologist 11:790-800